the Role of plin5 in the Development of Nonalcoholic Fatty Liver Disease.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

240 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-12-01

Study Completion Date

2025-12-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To further clarify the role of sequence polymorphism in patatin-like phospholipid domain containing protein 3 in the development of nonalcoholic fatty liver disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Liver Damage and Cardiometabolic Disorders in NAFLD

NCT04036357

NAFLD Liver Fibroses Cardiovascular Diseases +1 more

RECRUITING

Characterization of the Platelet Inflammatory Response in NAFL and NASH

NCT05128253

NASH - Nonalcoholic Steatohepatitis NAFLD

UNKNOWN

Pentoxifylline in Patients With Nonalcoholic Steatohepatitis

NCT00590161

Nonalcoholic Steatohepatitis

COMPLETED PHASE2

Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)

NCT07104201

Primary Biliary Cholangitis (PBC)

RECRUITING EARLY_PHASE1

Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).

NCT02173080

Polycystic Liver Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A sequence polymorphism in patatin-like phospholipid domain containing protein 3 is significantly associated with nonalcoholic fatty liver disease, but its mechanism underlying this association remains obscure. We introduce the human samples of liver to clarify the relationship between the expression of plin5 and the development of sequence polymorphism in patatin-like phospholipid domain containing protein 3 variant-associated nonalcoholic fatty liver disease, analyze the lipid metabolism and lipotoxicity of hepatocytes to elucidate the mechanisms of plin5 in the development of sequence polymorphism in patatin-like phospholipid domain containing protein 3 variant-associated nonalcoholic fatty liver disease. Our study will contribute to the mechanism of nonalcoholic fatty liver disease, and its prevention and therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-alcoholic Fatty Liver Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

The diagnosis of simple fatty liver disease was confirmed by clinical presentation, ultrasound, and without long-term drinking history, viral hepatitis, medication history, obesity (BMI≥30), type 2 diabetes and other metabolic diseases.